Drug Trial Radar · NCT04645069
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Mar 15, 2021
Primary completion
Jan 29, 2024
Study completion May 17, 2024
Sponsor
- Lead sponsor
- Adagene IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .
Conditions
- Advanced/Metastatic Solid Tumors
Interventions
ADG126 MonoBiological
ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.
ADG126-anti PD1Biological
ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion
ADG126-ADG106Biological
ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants experiencing dose-limiting toxicities escalating dose levels in adults with advanced / metastatic solid tumorsTime frame: From first dose of ADG126 (Week 1 Day 1) until 21 days
- Number of participants with adverse events as assessed by CTCAE v5.0 ADG126-ADG106 combination regimensTime frame: From first dose of ADG126 (Week 1 Day 1) to 90 days post last dose
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Next oncology
San Antonio, Texas
Southside Cancer Care Centre
Miranda, New South Wales, Australia
Macquarie University Hospital
Sydney, New South Wales, Australia
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia
Cabrini Health Limited
Malvern, Victoria, Australia
One Clinical Research Pty Ltd
Nedlands, Western Australia, Australia
National University Hospital
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.